Crestor Discounting Keeps Allergan's Generic Off UnitedHealth Formulary
This article was originally published in The Pink Sheet Daily
UnitedHealth will drop AstraZeneca's brand from coverage after competition drives down price of generic rosuvastatin.
You may also be interested in...
Company is waging the same legal battle Otsuka lost last year, arguing pediatric orphan indication should block approvals of ANDAs.
Allergan PLC's generic version of AstraZeneca PLC's blockbuster statin Crestor (rosuvastatin) is likely to need only a few weeks on the US market to surpass total sales of the PCSK9 inhibitors to date.
The mixed response to Merck's efforts to reach rebate agreements with health plans to place brand Zocor on the lowest cost-sharing tiers of their formularies suggests it is unlikely such a strategy would be broadly adopted by brand firms going forward